P/E ratio for Amedisys (AMED)
P/E ratio as of April 2024 (TTM): 908
According to Amedisys's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 907.8. At the end of 2022 the company had a P/E ratio of 22.9.
P/E ratio history for Amedisys from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 22.9 | -9.51% |
| 2021 | 25.3 | -51.45% |
| 2020 | 52.1 | 23.29% |
| 2019 | 42.3 | 31.71% |
| 2018 | 32.1 | -45.22% |
| 2017 | 58.6 | 53.87% |
| 2016 | 38.1 | -110.65% |
| 2015 | -357 | -574.98% |
| 2014 | 75.3 | -1663.77% |
| 2013 | -4.81 | 19.14% |
| 2012 | -4.04 | 389.82% |
| 2011 | -0.8246 | -109.92% |
| 2010 | 8.31 | -14.82% |
| 2009 | 9.76 | -22.81% |
| 2008 | 12.6 | -34.34% |
| 2007 | 19.3 | 2.66% |
| 2006 | 18.8 | -14.15% |
| 2005 | 21.8 | 5.23% |
| 2004 | 20.8 | 17.78% |
| 2003 | 17.6 | -137.94% |
| 2002 | -46.5 | -889.84% |
| 2001 | 5.88 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 LHC Group LHCG | 82.4 | -90.92% | 🇺🇸 USA |
 National Healthcare
NHC | 42.5 | -95.32% | 🇺🇸 USA |
 Chemed CHE | 36.7 | -95.96% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.